Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07643467 · ClinicalTrials.gov registry record · Phase 4
Fluorescent Probe for Assessment of Renal Elimination
A Phase 4 study, sponsored by Aaron Cook.
- Not yet
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT07643467: Clinical Trial Phase 4 study, sponsored by Aaron Cook.
NCT07643467 is a Phase 4 study that has not yet begun recruiting, run by Aaron Cook. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07643467, a Phase 4 study, has not yet begun recruiting, sponsored by Aaron Cook.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection \& other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.
Primary Outcome
Accuracy of transdermal glomerular filtration rate (GFR) monitoring compared with measured urine creatinine clearance.
Interventions
- DRUG Iohexol
- DRUG Relmapirazin
- DEVICE Medibeacon tGFR monitor
- DIAGNOSTIC_TEST Urine creatinine clearance collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 4 |
What is known before NCT07643467 opens enrollment
NCT07643467 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 4 interventions - of which Iohexol is the first listed.
NCT07643467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07643467 about?
NCT07643467 is a clinical study titled "Fluorescent Probe for Assessment of Renal Elimination". Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful fo...
What is the current status of trial NCT07643467?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2026-07. Estimated completion is 2028-06-30.
What interventions are being tested in trial NCT07643467?
The interventions under investigation include: Iohexol (DRUG), Relmapirazin (DRUG), Medibeacon tGFR monitor (DEVICE), Urine creatinine clearance collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07643467?
This trial is sponsored by Aaron Cook, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07643467's enrollment target sits among peer trials
200 407th of 2000 higher than 1,556 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia